P‐tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study
作者
Samantha C. Burnham,Haoyan B Hu,Yifeng Tang,Anthony N. Sireci,Michael J. Pontecorvo,Paul Ernest Schulz,Rosemary D. Laird,Curtis P. Schreiber,Rose C Beck
INTRODUCTION: Plasma biomarkers are minimally invasive tool for identifying Alzheimer's disease pathology. However, evaluation of their clinical utility remains limited. METHODS: = 218) arms. RESULTS: Change in working diagnosis was observed for 70.5% of patients with a t-tau217 result (positive or negative) inconsistent with baseline working diagnosis compared to 2.3% with a result consistent with baseline working diagnosis and 15.6% of untested patients. When the result was consistent with baseline working diagnosis, a significant 15.7% increase in diagnostic confidence was observed compared to 1.7% in untested patients and 5.0% when the result was inconsistent with baseline working diagnosis. DISCUSSION: P-tau217 testing changed health care providers' intended management and working diagnosis and increased confidence in the diagnosis. Highlights: Evaluation of the clinical utility of plasma tau phosphorylated at position 217 (p-tau217) for identifying Alzheimer's disease pathology has been limited.In this study, the impact of p-tau testing on health care providers' diagnostic thinking in patients under evaluation for cognitive impairment was assessed.When the result was inconsistent with the working diagnosis, a change in the working diagnosis was observed in 70.5% of tested patients.When the result was consistent, diagnostic confidence increased by 15.7%.P-tau217 testing demonstrated clinical utility by changing the working diagnosis, increasing diagnostic confidence, and altering intended patient management.